Agomelatine (Valdoxan®)

Assessment Status NCPE Assessment Process Complete
Drug Agomelatine
Brand Valdoxan®
Indication For the treatment of major depressive disorder.
Assessment Process
Full submission received from Applicant 01/04/2009
NCPE assessment completed 03/09/2009
NCPE assessment outcome Reimbursement not recommended

3rd September 2009 – At the current price agomelatine (Valdoxan®) is not considered cost-effective for the treatment of major depressive episodes under the Community Drugs Schemes.

11th December 2009 – Following a revision in price application we now consider agomelatine (Valdoxan®) cost effective under the Community Drugs schemes.  The product will now be added to the list of items reimbursable under the schemes.

Technical Summary